{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:03:41Z","timestamp":1792872221533,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Institute of Health","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}]},{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40291-025-00777-7","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T07:59:18Z","timestamp":1744012758000},"page":"393-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Actionability of Molecular Targets in Multi-Ethnic Breast Cancer Patients: A Retrospective Single-Institutional Study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-3853","authenticated-orcid":false,"given":"Irene","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Naghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Yost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"8","key":"777_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u201363.","journal-title":"N Engl J Med"},{"issue":"6","key":"777_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"18","key":"777_CR3","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Talazoparib: first global approval. Drugs. 2018;78(18):1939\u201346.","journal-title":"Drugs"},{"issue":"1","key":"777_CR4","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1002\/onco.13551","volume":"26","author":"S Arora","year":"2021","unstructured":"Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist. 2021;26(1):e164\u201372.","journal-title":"Oncologist"},{"issue":"7","key":"777_CR5","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","volume":"27","author":"P Narayan","year":"2021","unstructured":"Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, et al. FDA Approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res. 2021;27(7):1842\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"777_CR6","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.2217\/fon-2019-0468","volume":"16","author":"A Mavratzas","year":"2020","unstructured":"Mavratzas A, Seitz J, Smetanay K, Schneeweiss A, J\u00e4ger D, Fremd C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol (London, England). 2020;16(3):4439\u201353.","journal-title":"Future Oncol (London, England)."},{"issue":"22","key":"777_CR7","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370.","journal-title":"N Engl J Med"},{"key":"777_CR8","doi-asserted-by":"crossref","unstructured":"Bardia A, Bidard F-C, Neven P, Streich G, Montero AJ, Forget F, et al. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+\/HER2\u2212 metastatic breast cancer: updated results by duration of prior CDK4\/6i in metastatic setting. Cancer Res. 2023;83(5_Supplement):GS3-01-GS3-.","DOI":"10.1158\/1538-7445.SABCS22-GS3-01"},{"key":"777_CR9","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1016\/j.annonc.2022.03.152","volume":"33","author":"S Delaloge","year":"2022","unstructured":"Delaloge S, Giorgi Rossi P, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, et al. 135P Real-time genotyping-based breast cancer risk assessment in MyPeBS, an international randomized trial in the general population comparing risk-stratified to standard breast cancer screening (BCS). Ann Oncol. 2022;33:S184.","journal-title":"Ann Oncol"},{"issue":"5","key":"777_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101622","volume":"8","author":"E Rassy","year":"2023","unstructured":"Rassy E, Heard JM, Andre F. The paradigm shift to precision oncology between political will and cultural acceptance. ESMO Open. 2023;8(5): 101622.","journal-title":"ESMO Open."},{"issue":"7931","key":"777_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-05068-3","volume":"610","author":"F Andre","year":"2022","unstructured":"Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022;610(7931):343\u20138.","journal-title":"Nature"},{"issue":"11","key":"777_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023\u201331.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"777_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.5858\/arpa.2014-0200-OA","volume":"139","author":"JS Ross","year":"2015","unstructured":"Ross JS, Badve S, Wang K, Sheehan CE, Boguniewicz AB, Otto GA, et al. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Arch Pathol Lab Med. 2015;139(5):642\u20139.","journal-title":"Arch Pathol Lab Med"},{"issue":"7403","key":"777_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u201352.","journal-title":"Nature"},{"key":"777_CR15","doi-asserted-by":"crossref","unstructured":"Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucl Acids Res. 2015;43(Database issue):D805\u201311.","DOI":"10.1093\/nar\/gku1075"},{"issue":"1","key":"777_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med."},{"issue":"10031","key":"777_CR17","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"key":"777_CR18","doi-asserted-by":"crossref","unstructured":"Kowanetz MZ, Wei, Shames D, Cummings C, Rizvi N, Spira A, Frampton G, Leveque V, Flynn S, Mocci S, Shankar G, Funke R, Ballinger M, Waterkamp D, Chen D, Sandler A, Hampton G, Amler L, Hegde P, Hellmann M. OA20.01 tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients. J Thorac Oncol. 2017;12(15):S321\u2013S2.","DOI":"10.1016\/j.jtho.2016.11.343"},{"key":"777_CR19","doi-asserted-by":"crossref","unstructured":"Legrand FAG, David R, Mariathasan S, Powles T, He X, Zhang W, Jhunjhunwala S, Nickles D, Bourgon R, Schleifman E, Paul SM, Kadel EE, Kowanetz M, Cummings C, Li Y, Fabrizio D, Peters E, Hegde PS, Amler L, Shames DS. Association of high tissue TMB and atezolizumab efficacy across mutliple tumor types. J Clin Oncol. 2018;13(15_suppl):12000.","DOI":"10.1200\/JCO.2018.36.15_suppl.12000"},{"issue":"1","key":"777_CR20","doi-asserted-by":"publisher","first-page":"13624","DOI":"10.1038\/s41598-021-93084-0","volume":"11","author":"LA Stout","year":"2021","unstructured":"Stout LA, Kassem N, Hunter C, Philips S, Radovich M, Schneider BP. Identification of germline cancer predisposition variants during clinical ctDNA testing. Sci Rep. 2021;11(1):13624.","journal-title":"Sci Rep"},{"key":"777_CR21","doi-asserted-by":"crossref","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. 2017;377(6):523\u201333.","DOI":"10.1056\/NEJMoa1706450"},{"issue":"4","key":"777_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558\u201366.","journal-title":"Ann Oncol"},{"key":"777_CR23","doi-asserted-by":"crossref","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. 2018;379(8):753\u201363.","DOI":"10.1056\/NEJMoa1802905"},{"issue":"11","key":"777_CR24","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gon\u00e7alves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526\u201335.","journal-title":"Ann Oncol"},{"key":"777_CR25","doi-asserted-by":"crossref","unstructured":"Tung NM, Robson ME, Nanda R, Li T, Vinayak S, Shah PD, et al. TBCRC 048 (olaparib expanded) expansion cohorts: phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. 2024;42(16_suppl):1021.","DOI":"10.1200\/JCO.2024.42.16_suppl.1021"},{"key":"777_CR26","doi-asserted-by":"publisher","first-page":"1012391","DOI":"10.3389\/fonc.2022.1012391","volume":"12","author":"S Alaklabi","year":"2022","unstructured":"Alaklabi S, Roy AM, Attwood K, George A, O\u2019Connor T, Early A, et al. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: a single institution experience. Front Oncol. 2022;12:1012391.","journal-title":"Front Oncol"},{"issue":"2","key":"777_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2\u2013negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208\u201317.","journal-title":"Ann Oncol"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00777-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00777-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00777-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:02:22Z","timestamp":1746734542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00777-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00777-7","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"3 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by SCELC, Statewide California Electronic Library Consortium. Research reported in this publication includes work performed in the Pathology Research Services Core, Biostatistics and Mathematical Modeling Core, Integrative Genomics Core, and Bioinformatics Core supported\u00a0by the National Cancer Institute of the National Institutes of Health under award number P30CA033572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Kang has the following disclosures: consultant for Gilead, Caris Molecular Sciences, Pfizer, and Daiichi Sankyo. Dr. Mortimer has nothing to disclose. Dr. Yost has nothing to disclose. Dr. Naghi has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data are available upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of City of Hope\u2019s internal review board (IRB) and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Tumor specimens were identified through a City of Hope IRB-approved retrospective protocol for patients consented to City of Hope Biorepository Protocol IRB 07047, and genomic analysis was performed under City of Hope IRB 15325.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all participants on this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design: JM, SEY. Acquisition of data: SEY, LN. Analysis and interpretation of data (e.g., statistical analyses, biostatistics, computational analyses): all authors. Writing, review, and\/or revision of the manuscript: all authors. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): SEY. Study supervision: JM; All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}